Like Gilead, Achillion Should Trade Up On Bad News For Bristol-Myers, Idenix ... - Reuters

Like Gilead, Achillion Should Trade Up On Bad News For Bristol-Myers, Idenix ... Reuters With Gilead (NASDAQ:GILD) paying $11 billion for Pharmasset last year, the action around the next generation of hepatitis C treatments has centered on nucleoside type products ("the nukes"). With Bristol-Myers (NYSE:BMY) halting clinical trials for its ... and more »